These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 17343986)
41. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? Kleespies A; Jauch KW; Bruns CJ Drug Resist Updat; 2006; 9(1-2):1-18. PubMed ID: 16621676 [TBL] [Abstract][Full Text] [Related]
42. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K Oncology; 2004; 66(1):32-7. PubMed ID: 15031596 [TBL] [Abstract][Full Text] [Related]
43. Smarter drugs emerging in pancreatic cancer therapy. Kleger A; Perkhofer L; Seufferlein T Ann Oncol; 2014 Jul; 25(7):1260-1270. PubMed ID: 24631947 [TBL] [Abstract][Full Text] [Related]
44. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Crane CH; Mason K; Janjan NA; Milas L Am J Clin Oncol; 2003 Aug; 26(4):S81-4. PubMed ID: 12902862 [TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant Treatment for Pancreatic Cancer. Raufi AG; Manji GA; Chabot JA; Bates SE Semin Oncol; 2019 Feb; 46(1):19-27. PubMed ID: 30630600 [TBL] [Abstract][Full Text] [Related]
46. New target therapies in advanced pancreatic cancer. Cascinu S; Verdecchia L; Valeri N; Berardi R; Scartozzi M Ann Oncol; 2006 May; 17 Suppl 5():v148-52. PubMed ID: 16807445 [TBL] [Abstract][Full Text] [Related]
47. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869 [TBL] [Abstract][Full Text] [Related]
48. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509 [TBL] [Abstract][Full Text] [Related]
49. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. Inal A; Kos FT; Algin E; Yildiz R; Dikiltas M; Unek IT; Colak D; Elkiran ET; Helvaci K; Geredeli C; Dane F; Balakan O; Kaplan MA; Durnali AG; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Kucukoner M; Ozkan M; Uncu D; Benekli M; Isikdogan A Neoplasma; 2012; 59(3):297-301. PubMed ID: 22329849 [TBL] [Abstract][Full Text] [Related]
50. Treatment of advanced pancreatic cancer. Ducreux M; Boige V; Malka D Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349 [TBL] [Abstract][Full Text] [Related]
52. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Larbouret C; Robert B; Bascoul-Mollevi C; Penault-Llorca F; Ho-Pun-Cheung A; Morisseau S; Navarro-Teulon I; Mach JP; Pèlegrin A; Azria D Ann Oncol; 2010 Jan; 21(1):98-103. PubMed ID: 19889608 [TBL] [Abstract][Full Text] [Related]
53. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Hecht JR; Bedford R; Abbruzzese JL; Lahoti S; Reid TR; Soetikno RM; Kirn DH; Freeman SM Clin Cancer Res; 2003 Feb; 9(2):555-61. PubMed ID: 12576418 [TBL] [Abstract][Full Text] [Related]